NASDAQ: PRPH
Prophase Labs Inc Stock

$0.33+0.00 (+0%)
Updated Jun 16, 2025
PRPH Price
$0.33
Fair Value Price
N/A
Market Cap
$13.83M
52 Week Low
$0.22
52 Week High
$4.68
P/E
-0.15x
P/B
0.92x
P/S
3.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.57M
Earnings
-$43.13M
Gross Margin
17.7%
Operating Margin
-656.84%
Profit Margin
-944.4%
Debt to Equity
2.32
Operating Cash Flow
-$16M
Beta
0.94
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PRPH Overview

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PRPH's potential to beat the market

Zen Rating Component Grades

N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Diagnostic & Research

Industry Rating
C
PRPH
Ranked
Unranked of 42

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$47.45A
$14.21A
$90.25B
View Top Diagnostic & Research Stocks

Be the first to know about important PRPH news, forecast changes, insider trades & much more!

PRPH News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRPH scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PRPH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRPH is good value based on its book value relative to its share price (0.92x), compared to the US Diagnostics & Research industry average (3.5x)
P/B vs Industry Valuation
PRPH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more PRPH due diligence checks available for Premium users.

Valuation

PRPH fair value

Fair Value of PRPH stock based on Discounted Cash Flow (DCF)

Price
$0.33
Fair Value
-$0.31
Undervalued by
206.89%
PRPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PRPH price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.15x
Industry
19.86x
Market
29.27x

PRPH price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.92x
Industry
3.5x
PRPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PRPH's financial health

Profit margin

Revenue
$1.4M
Net Income
$4.0M
Profit Margin
277.1%
PRPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PRPH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$50.1M
Liabilities
$35.0M
Debt to equity
2.32
PRPH's short-term assets ($24.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRPH's short-term assets ($24.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PRPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.4M
Investing
$853.0k
Financing
$1.9M
PRPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PRPH vs Diagnostic & Research Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PRPH$13.83M+0.60%-0.15x0.92x
PRPO$16.46M+0.32%-5.23x1.41x
TRIB$11.21M-1.73%-0.35x-0.32x
MDXH$9.85M-0.50%-0.19x1.65x
ADVB$19.95M-3.96%N/A4.83x

Prophase Labs Stock FAQ

What is Prophase Labs's quote symbol?

(NASDAQ: PRPH) Prophase Labs trades on the NASDAQ under the ticker symbol PRPH. Prophase Labs stock quotes can also be displayed as NASDAQ: PRPH.

If you're new to stock investing, here's how to buy Prophase Labs stock.

What is the 52 week high and low for Prophase Labs (NASDAQ: PRPH)?

(NASDAQ: PRPH) Prophase Labs's 52-week high was $4.68, and its 52-week low was $0.22. It is currently -92.88% from its 52-week high and 52.75% from its 52-week low.

How much is Prophase Labs stock worth today?

(NASDAQ: PRPH) Prophase Labs currently has 41,541,205 outstanding shares. With Prophase Labs stock trading at $0.33 per share, the total value of Prophase Labs stock (market capitalization) is $13.83M.

Prophase Labs stock was originally listed at a price of $14.44 in Dec 31, 1997. If you had invested in Prophase Labs stock at $14.44, your return over the last 27 years would have been -97.69%, for an annualized return of -13.03% (not including any dividends or dividend reinvestments).

How much is Prophase Labs's stock price per share?

(NASDAQ: PRPH) Prophase Labs stock price per share is $0.33 today (as of Jun 16, 2025).

What is Prophase Labs's Market Cap?

(NASDAQ: PRPH) Prophase Labs's market cap is $13.83M, as of Jun 17, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Prophase Labs's market cap is calculated by multiplying PRPH's current stock price of $0.33 by PRPH's total outstanding shares of 41,541,205.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.